Rimonabant acomplia is a new revolutionary drug developed by French company Sanofi. During the test period Acomplia has shown great promise for the treatment obesity and additional risk body issues.
Drug is already approved in some European countries - Ireland, Sweden, Norway, Germany and U.K. Trade name is Acomplia. In USA, Acomplia is awaiting approval from FDA office /probably April 2007/.Trade mark for USA should be Rimonabant Zimulti.
Rimonabant works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System).
Human tests began in 2002 and demonstrated a significant reduction in abdominal obesity, an independent marker for heart disease.
Acomplia also improves cardiovascular/ metabolic risk factors in overweight/obese patients. Dramatic health corections were reported in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides (bad cholesterol). Prices of Rimonabant Acomplia are around 3 - 3.8 Euro per pill.
Article Source: http://www.fitnesshealtharticles.com.
About the Author:
You can read much more about Acomplia here:Acomplia
Zimulti Acomlia.
Rimonabant Acomplia - general information
